October 17, 2017 / 12:43 PM / a year ago

BRIEF-Tonix Pharma reports outcomes from CMC guidance meeting with FDA on Tonmya

Oct 17 (Reuters) - Tonix Pharmaceuticals Holding Corp

* Tonix Pharmaceuticals reports outcomes from U.S. FDA breakthrough therapy CMC guidance meeting of Tonmya® (cyclobenzaprine hci sublingual tablets) for PTSD

* Tonix Pharmaceuticals Holding Corp - ‍proposed CMC data package to support Tonmya’s NDA and commercial manufacturing plans was accepted by FDA​

* Tonix Pharmaceuticals Holding - ‍FDA official minutes reflect co’s readiness to manufacture Tonmya commercial product at production scale​

* Tonix Pharmaceuticals Holding - ‍Tonmya has been conditionally accepted by FDA as proposed trade name for TNX-102 SL (cyclobenzaprine hcl sublingual tablets) for PTSD​ Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below